

TRANSMITTAL OF SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT UNDER 37 CFR § 1.97(b),
1.97(c), or 1.97(d)

Attny. Docket No.
2002B129/2

In Re Application of: Lustiger, et al.

U.S. Serial No.
10/666,713

Filing Date
09/18/2003

Examiner
Roberto Rabago

Group Art Unit
1713

Address to:

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

37 CFR § 1.97(b)

The Information Disclosure Statement submitted herewith is being filed within three months of the filing date of a national application other than a continued prosecution application under § 1.53(d); within three months of the date of entry of the national stage as set forth in § 1.491 in an international application; before the mailing of a first Office Action on the merits; or before the mailing of a first Office Action after the filing of a request for continued examination under § 1.114.

37 CFR § 1.97(c)

The Information Disclosure Statement submitted herewith is being filed after three months of the filing date of a national application other than a continued prosecution application under § 1.53(d); after three months of the date of entry of the national stage as set forth in § 1.491 in an international application; after the mailing of a first Office Action on the merits; or after the mailing of a first Office Action after the filing of a request for continued examination under § 1.114, but before the mailing date of:

1. a Final Action under § 1.113,
2. a Notice of Allowance under § 1.311, or
3. an action that otherwise closes prosecution in the application,

and is accompanied by either:



the fee as set forth in § 1.17(p), or
 the following statement under § 1.97(e)(1): each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement.

37 CFR § 1.97(d)

The Information Disclosure Statement submitted herewith is being filed after a Final Action under § 1.113, a Notice of Allowance under § 1.311, or an action that otherwise closes prosecution in the application, but before, or simultaneously with, the payment of the issue fee. Submitted herewith is the fee as set forth in § 1.17(p) and the following statement under 37 CFR § 1.97(e)(1): each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement.

Applicant hereby request consideration of the Information Disclosure Statement, USPTO form 1449, submitted herewith.

Legible copies of references are enclosed where necessary.

This application is a:
 Continuation / Divisional,
 Continuation-in-Part,

The Commissioner is hereby authorized to charge any additional fees which may be required by this paper, or credit any overpayment, to Deposit Account Number 05-1712. A duplicate copy of this form is enclosed.

4 March 2005

Date

maigcell

Maria C. Walsh
Registration No. 37,958
ExxonMobil Chemical Company
Law Technology
P.O. Box 2149
Baytown, Texas 77522-2149
(281) 834-1076 Voice
(281) 834-2495 Facsimile

<p style="text-align: center;">SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT <i>(Use several sheets if necessary)</i></p>				ATTY. DOCKET NO.	SERIAL NO.		
				2002B129/2	10/666,710		
				APPLICANT			
				Lustiger, et al.			
				FILING DATE	GROUP		
				09/18/2003	1713		
U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA	5,858,491	1/12/1999	Geussens et al.	428	36.9	
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	PUBL. DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
	AL	2001-89615	04/2001	Japan	C08L	23/06	<input checked="" type="checkbox"/> YES <input type="checkbox"/> NO
	AM	199921280	9/30/99	Australia	C08L	23/06	
	AN						
	AO						
OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages of Publication, Etc.)							
	AP						
	AQ						
EXAMINER				DATE CONSIDERED			
<p>*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line though citation if not in conformance and not considered. Include copy of this form with next comment to applicant</p>							